To view or add a comment, sign in The FDA recently approved an ORAL therapy, Ekterly (sebetralstat) from KalVista Pharmaceuticals, indicated as an oral treatment for acute hereditary angioedema (HAE) attacks in patients aged 12 and older, after a delay attributed to FDA resource constraints
As reports show, with the expiry of Novo Nordisks semaglutide exclusivity on January 4, 2026, Canada has emerged as the first major Western market where generic semaglutide can be legally produced and sold, subject to Health Canada approval
Studies have also found improvements in cognitive tasks and reduced brain fog among users
And I was like, "Thank God for bench press." These are practical applications
Archived from the original on 2012-09-05